OR WAIT 15 SECS
Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine
PHILADELPHIA, PA, November 6, 2007-Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)’s 56th annual meeting held in Philadelphia, Pennsylvania, USA. These results have prompted Sanofi Pasteur to immediately expand ongoing clinical trials in Asia and Latin America. Submission to health authorities for registration is anticipated in 2012.
“Sanofi Pasteur made research for a vaccine against dengue fever one of its top priorities by investing in the most promising technology and dedicating top scientists to this lifesaving project,” said Wayne Pisano, president and chief executive officer of Sanofi Pasteur. “Sanofi Pasteur’s goal is to make dengue fever a vaccine-preventable disease as quickly as possible with a vaccine available to people living in endemic countries or traveling to tropical destinations.”
Immunization with Sanofi Pasteur’s tetravalent dengue candidate vaccine generated a sero-neutralizing antibody response against all four serotypes of the virus responsible for dengue fever in 100 percent of adults who participated in a trial in the United States.